MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA – Get Free Report) Director Stan Smith purchased 25,000 shares of the stock in a transaction on Friday, December 13th. The shares were purchased at an average price of $1.87 per share, with a total value of $46,750.00. Following the acquisition, the director now owns 1,130,060 shares in the company, valued at approximately $2,113,212.20. The trade was a 2.26 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
MAIA Biotechnology Stock Down 0.5 %
MAIA opened at $2.00 on Friday. The firm has a market cap of $50.66 million, a PE ratio of -1.45 and a beta of 0.14. MAIA Biotechnology, Inc. has a twelve month low of $0.85 and a twelve month high of $5.99.
MAIA Biotechnology (NYSEAMERICAN:MAIA – Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.21. As a group, research analysts anticipate that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current fiscal year.
Hedge Funds Weigh In On MAIA Biotechnology
MAIA Biotechnology Company Profile
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
Further Reading
- Five stocks we like better than MAIA Biotechnology
- Roth IRA Calculator: Calculate Your Potential Returns
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Canada Bond Market Holiday: How to Invest and Trade
- Texas Instruments: The Old-School Tech Titan Still Delivering
- ETF Screener: Uses and Step-by-Step Guide
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for MAIA Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAIA Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.